Loading...
•
Mar 31, 2024
Establishment Labs Q1 2024 Earnings Report
Establishment Labs experienced a mixed first quarter, with revenue decreasing year-over-year but gross profit margin increasing. Operating expenses were reduced, and the company is progressing towards FDA approval for Motiva Implants.
Key Takeaways
Establishment Labs reported a decrease in revenue for the first quarter of 2024 compared to the same period in 2023, but saw an increase in gross profit margin. The company reduced operating expenses and is making progress with FDA approval for Motiva Implants. Revenue guidance for 2024 remains between $174 million and $184 million.
First quarter worldwide revenue was $37.2 million.
Gross profit for the first quarter was $24.4 million, representing 65.6% of revenue.
Loss from operations was $8.8 million, improved from the fourth quarter of 2023.
Cash balance was $73.0 million as of March 31, 2024.
Forward Guidance
Establishment Labs anticipates continued improvement throughout the year, driven by market stabilization and expense reduction initiatives. The company expects U.S. FDA approval of Motiva this year and is preparing for the launch.
Positive Outlook
- Market demand is stabilizing.
- Continued improvement is expected over the course of the year.
- Meaningful steps have been taken to reduce the expense base.
- Adjusted EBITDA improved significantly.
- U.S. FDA approval of Motiva is expected this year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...